Back to Results

Medmira Inc (MMIRF)

MedMira Inc. is a common stock listing on OTC Markets for MedMira Inc., a biotechnology company focused on rapid diagnostics and related technology platforms. The company develops, manufactures, and sells diagnostic products in North America, Europe, and other international markets. Its portfolio includes Reveal HIV, Reveal TP for syphilis screening, the Multiplo line of multiplex tests covering HIV-1/2, hepatitis B and C, and syphilis, as well as the Miriad triple product for preliminary HIV and hepatitis screening. MedMira also provides the Miriad RVF toolkit for developing and commercializing rapid diagnostics and offers Reveal G4 HIV tests. Founded in 1993 and headquartered in Halifax, Canada, the company operates as a subsidiary of MedMira Holding AG.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-MMIR.F
Not available
Not available
Not available
Weak
0.0%
November 27, 2026
123.1x
32.428 M
46.404 M
27.6%
29.9%
-150.9
39.7%
Valuation • Fair Value

Medmira Inc (OTC-MMIR.F) Fair Value by Valuation Model

No usable valuation estimate is currently available for Medmira Inc (OTC-MMIR.F); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Medmira Inc (OTC-MMIR.F). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Medmira Inc (OTC-MMIR.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

272.801 K

Current operating scale indicator.

Revenue Forecast

171.575 K

Forward revenue estimate.

EBITDA

-1.428 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Medmira Inc (OTC-MMIR.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Medmira Inc (OTC-MMIR.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-3.92

No elevated caution signal from this screen.

Altman Z-Score

-150.9

Lower score that deserves closer risk review.

FCF / Net Income

39.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Medmira Inc (OTC-MMIR.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Medmira Inc (OTC-MMIR.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 27, 2026

Days to Earnings

66

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Medmira Inc (OTC-MMIR.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Medmira Inc (OTC-MMIR.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Medmira Inc (OTC-MMIR.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Medmira Inc (OTC-MMIR.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Medmira Inc (OTC-MMIR.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Medmira Inc (OTC-MMIR.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Medmira Inc (OTC-MMIR.F) Stock FAQ

Data-supported answers about Medmira Inc (OTC-MMIR.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Weak
Current financial-health read

A reliable fair value estimate is not currently available for Medmira Inc (OTC-MMIR.F). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Medmira Inc (OTC-MMIR.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Medmira Inc (OTC-MMIR.F) is November 27, 2026.

The latest available data indicates no current dividend yield for Medmira Inc (OTC-MMIR.F).

The current market capitalization listed for Medmira Inc is 32.428 M.

The current enterprise value listed for Medmira Inc is 46.404 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Medmira Inc is OTC-MMIR.F, and the stock is listed on OTC Markets.

Medmira Inc (OTC-MMIR.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Medmira Inc is 27.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Medmira Inc is 29.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 179.4 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 142 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 116.1 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 65.099 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 51.173 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.847 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 44.185 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 41.084 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 33.785 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 31.756 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.674 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 29.933 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.452 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 20.357 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 17.926 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.107 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.581 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 12.242 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.566 B